LivaNova PLC (LIVN) shares surged 10.64% in pre-market trading on Wednesday following the release of better-than-expected first-quarter results and encouraging data from a clinical study on sleep apnea treatment.
The medical technology company reported Q1 revenue of $316.9 million, surpassing the IBES estimate of $302.3 million. Adjusted earnings per share came in at $0.88, significantly higher than the expected $0.76. LivaNova also raised its full-year 2025 revenue growth guidance to 6.0% to 7.0% on a constant-currency basis, up from the previous range of 5.0% to 6.0%.
Adding to the positive sentiment, LivaNova announced promising 12-month data from its OSPREY clinical study for moderate to severe obstructive sleep apnea. The study demonstrated strong response and durability of therapy, with an overall responder rate of 65% and a 68% reduction in both the median Apnea-Hypopnea Index and Oxygen Desaturation Index. These results, along with the company's recent premarket approval submission to the FDA for its aura6000 System, suggest potential future growth in the sleep apnea market.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。